Alternative donor hematopoietic stem cell transplantation for sickle cell disease in Europe.


Journal

Hematology/oncology and stem cell therapy
ISSN: 2589-0646
Titre abrégé: Hematol Oncol Stem Cell Ther
Pays: Saudi Arabia
ID NLM: 101468532

Informations de publication

Date de publication:
Dec 2020
Historique:
received: 31 10 2019
accepted: 11 12 2019
pubmed: 24 3 2020
medline: 27 3 2021
entrez: 24 3 2020
Statut: ppublish

Résumé

Allogeneic hematopoietic stem cell transplantation (HSCT) is, to date, the only curative treatment for sickle cell disease (SCD). Because an human leukocyte antigen (HLA)-matched sibling donor is not always available, alternative stem cell sources such as unrelated or haploidentical related donors have been explored. To date, few series of SCD patients transplanted with an unrelated donor, cord blood, and haploidentical related donor have been reported, but the high rates of rejection and chronic graft versus host disease have limited their widespread application. We describe the outcomes of a retrospective, registry-based, survey on 144 alternative donor HSCT performed for SCD in 30 European Society for Blood and Marrow Transplantation centers between 1999 and 2017. Data on 70 unrelated adult donors (49%), six cord blood (4%), and 68 haploidentical donors (47%; including post-HSCT Cy, ex vivo T-cell depleted, and other haplo-HSCTs) were reported and missing information was updated by the centers. Overall, 16% patients experienced graft failure, Grade II-IV acute GVHD at 100 days was 24%, whereas Grade III-IV was 10%. Chronic GVHD was observed in 24% (limited for 13 patients and extensive for 18 patients). Overall, the 3-year overall survival (OS) was 86% ± 3% and 3-year event-free survival (EFS; considering death and graft failure as events) was 72% ± 4%. We therefore conclude that alternative donor HSCT for SCD can be feasible but efforts in decreasing relapse and GVHD should be promoted to increase its safe and successful utilization. Moreover, a better knowledge of HLA matching and the tailoring of conditioning could help improve EFS and OS.

Identifiants

pubmed: 32201153
pii: S1658-3876(20)30034-0
doi: 10.1016/j.hemonc.2019.12.011
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

181-188

Informations de copyright

Copyright © 2020 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Eliane Gluckman (E)

Monacord, Centre Scientifique de Monaco, Monaco; Eurocord, Hôpital Saint Louis, Universite Paris Diderot, Paris, France. Electronic address: eliane.gluckman@aphp.fr.

Barbara Cappelli (B)

Monacord, Centre Scientifique de Monaco, Monaco; Eurocord, Hôpital Saint Louis, Universite Paris Diderot, Paris, France.

Graziana Maria Scigliuolo (GM)

Monacord, Centre Scientifique de Monaco, Monaco; Eurocord, Hôpital Saint Louis, Universite Paris Diderot, Paris, France.

Josu De la Fuente (J)

Department of Pediatrics, St Mary's Hospital, Imperial College, London, UK.

Selim Corbacioglu (S)

Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, University of Regensburg, Regensburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH